TY - JOUR T1 - <em>KRAS</em> Genotyping as Biomarker in Colorectal Cancer: A Comparison of Three Commercial Kits on Histologic Material JF - Anticancer Research JO - Anticancer Res SP - 5251 LP - 5256 VL - 30 IS - 12 AU - ALDO CAVALLINI AU - ANNA MARIA VALENTINI AU - CATIA LIPPOLIS AU - DANIELA CAMPANELLA AU - VITO GUERRA AU - MARIA LUCIA CARUSO Y1 - 2010/12/01 UR - http://ar.iiarjournals.org/content/30/12/5251.abstract N2 - Background/Aim: The crucial role of KRAS status in new colorectal cancer target therapy raises the issue regarding which testing method to use. This study analysed 112 formalin fixed, paraffin-embedded (FFPE) metastatic tissue samples using three different commercially available kits. Patients and Methods: A group of 40 KRAS wild-type (wt), 40 codon 12-mutated and 32 codon-13 mutated samples, previously evaluated by real-time PCR (TheraScreen kit), used as reference method, were analysed by Ampli-set-K-RAS and K-RAS StripAssay kit (herein called kit A and B, respectively) based on two different technologies. Results: The sensitivity of both kits was 92.5% for wt samples, 100% and 95.0% for kit A and B, respectively for samples mutated in codon 12. The specificity was 100% for both kits for all groups of samples. After a minor modification of the kit A method, its specificity reached 100%. Conclusion: of low cost and easy to use, kit A may be suitable for use in a routine diagnostic setting. ER -